Cargando…

Imputation methods for missing outcome data in meta-analysis of clinical trials

BACKGROUND: Missing outcome data from randomized trials lead to greater uncertainty and possible bias in estimating the effect of an experimental treatment. An intention-to-treat analysis should take account of all randomized participants even if they have missing observations. PURPOSE: To review an...

Descripción completa

Detalles Bibliográficos
Autores principales: Higgins, Julian PT, White, Ian R, Wood, Angela M
Formato: Texto
Lenguaje:English
Publicado: Sage 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2602608/
https://www.ncbi.nlm.nih.gov/pubmed/18559412
http://dx.doi.org/10.1177/1740774508091600
_version_ 1782162518360195072
author Higgins, Julian PT
White, Ian R
Wood, Angela M
author_facet Higgins, Julian PT
White, Ian R
Wood, Angela M
author_sort Higgins, Julian PT
collection PubMed
description BACKGROUND: Missing outcome data from randomized trials lead to greater uncertainty and possible bias in estimating the effect of an experimental treatment. An intention-to-treat analysis should take account of all randomized participants even if they have missing observations. PURPOSE: To review and develop imputation methods for missing outcome data in meta-analysis of clinical trials with binary outcomes. METHODS: We review some common strategies, such as simple imputation of positive or negative outcomes, and develop a general approach involving ‘informative missingness odds ratios’ (IMORs). We describe several choices for weighting studies in the meta-analysis, and illustrate methods using a meta-analysis of trials of haloperidol for schizophrenia. RESULTS: IMORs describe the relationship between the unknown risk among missing participants and the known risk among observed participants. They are allowed to differ between treatment groups and across trials. Application of IMORs and other methods to the haloperidol trials reveals the overall conclusion to be robust to different assumptions about the missing data. LIMITATIONS: The methods are based on summary data from each trial (number of observed positive outcomes, number of observed negative outcomes and number of missing outcomes) for each intervention group. This limits the options for analysis, and greater flexibility would be available with individual participant data. CONCLUSIONS: We propose that available reasons for missingness be used to determine appropriate IMORs. We also recommend a strategy for undertaking sensitivity analyses, in which the IMORs are varied over plausible ranges.
format Text
id pubmed-2602608
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Sage
record_format MEDLINE/PubMed
spelling pubmed-26026082009-01-26 Imputation methods for missing outcome data in meta-analysis of clinical trials Higgins, Julian PT White, Ian R Wood, Angela M Clin Trials Article BACKGROUND: Missing outcome data from randomized trials lead to greater uncertainty and possible bias in estimating the effect of an experimental treatment. An intention-to-treat analysis should take account of all randomized participants even if they have missing observations. PURPOSE: To review and develop imputation methods for missing outcome data in meta-analysis of clinical trials with binary outcomes. METHODS: We review some common strategies, such as simple imputation of positive or negative outcomes, and develop a general approach involving ‘informative missingness odds ratios’ (IMORs). We describe several choices for weighting studies in the meta-analysis, and illustrate methods using a meta-analysis of trials of haloperidol for schizophrenia. RESULTS: IMORs describe the relationship between the unknown risk among missing participants and the known risk among observed participants. They are allowed to differ between treatment groups and across trials. Application of IMORs and other methods to the haloperidol trials reveals the overall conclusion to be robust to different assumptions about the missing data. LIMITATIONS: The methods are based on summary data from each trial (number of observed positive outcomes, number of observed negative outcomes and number of missing outcomes) for each intervention group. This limits the options for analysis, and greater flexibility would be available with individual participant data. CONCLUSIONS: We propose that available reasons for missingness be used to determine appropriate IMORs. We also recommend a strategy for undertaking sensitivity analyses, in which the IMORs are varied over plausible ranges. Sage 2008 /pmc/articles/PMC2602608/ /pubmed/18559412 http://dx.doi.org/10.1177/1740774508091600 Text en © Society for Clinical Trials 2008 http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Higgins, Julian PT
White, Ian R
Wood, Angela M
Imputation methods for missing outcome data in meta-analysis of clinical trials
title Imputation methods for missing outcome data in meta-analysis of clinical trials
title_full Imputation methods for missing outcome data in meta-analysis of clinical trials
title_fullStr Imputation methods for missing outcome data in meta-analysis of clinical trials
title_full_unstemmed Imputation methods for missing outcome data in meta-analysis of clinical trials
title_short Imputation methods for missing outcome data in meta-analysis of clinical trials
title_sort imputation methods for missing outcome data in meta-analysis of clinical trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2602608/
https://www.ncbi.nlm.nih.gov/pubmed/18559412
http://dx.doi.org/10.1177/1740774508091600
work_keys_str_mv AT higginsjulianpt imputationmethodsformissingoutcomedatainmetaanalysisofclinicaltrials
AT whiteianr imputationmethodsformissingoutcomedatainmetaanalysisofclinicaltrials
AT woodangelam imputationmethodsformissingoutcomedatainmetaanalysisofclinicaltrials